Liu Yang, Liu Xin, Sun Shiran, Han Yaqian, Feng Mei, Zhang Ye, Wang Kai, Qu Yuan, Chen Xuesong, Zhang Jianghu, Luo Jingwei, Wu Runye, Li Yexiong, Huang Xiaodong, Guo Shanshan, Wang Jingbo, Yi Junlin
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Department of Radiation Oncology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan Province, 410013, China.
Lancet Reg Health West Pac. 2024 Jul 19;49:101147. doi: 10.1016/j.lanwpc.2024.101147. eCollection 2024 Aug.
The survival rates of patients with nasopharyngeal carcinoma (NPC) have improved significantly, but there is no consensus on whether they can be considered cured. We aimed to determine whether a statistical cure could be achieved for patients with NPC in the contemporary therapeutic landscape.
This retrospective multicenter study enrolled 6315 patients with nonmetastatic NPC from nonendemic and endemic regions of China from 2007 to 2020. We applied mixture and nonmixture cure models to estimate the cure probabilities and cure times by incorporating background mortality for the general population, matching by gender, age, and diagnosed year.
With death as the uncured event, the probability of patients with NPC achieving a life expectancy at par with the general population was 78.1%. Considering progression as the uncured event, the likelihood of patients attaining a life expectancy without progression equivalent to that of the general population was 72.4%. For individuals, the probabilities of achieving cure were conditional and time-dependent, requiring approximately 7.1 and 4.7 years with 95% certainty, respectively. The corresponding cure times for uncured patients were 8.9 and 6.8 years, respectively. The cure probability was correlated with age, Eastern Cooperative Oncology Group score, TNM staging, Epstein-Barr virus DNA copies, and lactate dehydrogenase. The correlation was excellent between 5-year overall survival/progression-free survival and cure fractions.
Statistical cure is potentially achievable among patients with NPC undergoing contemporary treatment modalities. The results hold significant potential implications for both clinical practice and patient perspectives.
National High Level Hospital Clinical Research Funding; Beijing Xisike Clinical Oncology Research Foundation; Beijing hope run fund.
鼻咽癌(NPC)患者的生存率有了显著提高,但对于他们是否可被视为治愈尚无共识。我们旨在确定在当代治疗环境下,鼻咽癌患者是否能实现统计学上的治愈。
这项回顾性多中心研究纳入了2007年至2020年来自中国非流行和流行地区的6315例非转移性鼻咽癌患者。我们应用混合和非混合治愈模型,通过纳入一般人群的背景死亡率,按性别、年龄和诊断年份进行匹配,来估计治愈概率和治愈时间。
以死亡作为未治愈事件,鼻咽癌患者达到与一般人群相当的预期寿命的概率为78.1%。将疾病进展视为未治愈事件,患者达到与一般人群相当的无进展预期寿命的可能性为72.4%。对于个体而言,实现治愈的概率是有条件的且随时间变化,分别需要约7.1年和4.7年,置信度为95%。未治愈患者的相应治愈时间分别为8.9年和6.8年。治愈概率与年龄、东部肿瘤协作组评分、TNM分期、爱泼斯坦-巴尔病毒DNA拷贝数和乳酸脱氢酶相关。5年总生存/无进展生存与治愈比例之间的相关性良好。
接受当代治疗方式的鼻咽癌患者有可能实现统计学上的治愈。这些结果对临床实践和患者认知都具有重要潜在意义。
国家高水平医院临床研究资助;北京西斯科临床肿瘤研究基金会;北京希望马拉松基金。